[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633036":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":36,"centralContacts":41,"locations":26,"responsibleParty":51,"collaborators":26,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":26,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":26,"enrollmentInfo":62,"targetDuration":26,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":77,"whyStopped":26,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":26},{"fullName":5,"class":6},"ISISPHARMA","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Split-Face dermocosmetic","EXPERIMENTAL","Participants receive both treatments in a split-face design, with the dermocosmetic product applied to one side of the face and placebo applied to the opposite side. Treatments are applied twice daily.",[13,14],"Other: Dermocosmetic tested product","Device: Vascular laser treatment",{"label":16,"type":17,"description":11,"interventionNames":18},"Split-Face placebo","PLACEBO_COMPARATOR",[19,14],"Other: Placebo",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"OTHER","Dermocosmetic tested product","The dermocosmetic product will be applied topically to one side of the face twice daily.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","The placebo is a dermocosmetic formulation identical in appearance, texture, and application to the active product but without active ingredients. It is applied topically to the opposite side of the face twice daily, following the same regimen as the active product.",[16],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":26},"DEVICE","Vascular laser treatment","Participants receive three sessions of vascular laser treatment performed at regular intervals during the study. Laser therapy is used as part of standard care to target facial redness and visible blood vessels. The dermocosmetic product and placebo continue to be applied as adjunct treatments during this phase.",[9,16],[37],{"name":38,"affiliation":39,"role":40},"Olivia BAUVIN, Doctor of Medicine","Department of Dermatology and Venereology, Charles-Nicolle Hospital, Rouen, FRANCE","PRINCIPAL_INVESTIGATOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":26,"email":46},"Chloe GOYET, Master degree","CONTACT","+33 627806219","cgoyet@isispharma.com",{"name":48,"role":44,"phone":49,"phoneExt":26,"email":50},"Amelie CLEMENT, Engineering degree","+33 6 29 76 53 54","aclement@isispharma.com",{"type":52,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100633036","dermocosmetic-treatment-for-facial-redness-in-rosacea-with-or-without-laser-therapy-100633036",false,"NCT07521462","Dermocosmetic Treatment for Facial Redness in Rosacea With or Without Laser Therapy","Impact of Using a Dermocosmetic Product as Monotherapy or as an Adjunct to Laser Treatment on Redness Associated With Erythematotelangiectatic Rosacea: a Comparative Study Versus Placebo.","Inclusion Criteria:\n\n* Gender: male or female\n* Age: \\> 18 years -Patients with mild to severe erythro-couperotic rosacea (stage 2, 3, or 4 - TRoSA scale, section 2.2.3.1)\n* Patients wishing to undergo vascular laser treatments for their rosacea\n* Patients who have provided informed consent\n\nExclusion Criteria:\n\n* Pregnant patients or patients with a positive urine pregnancy test at the initial visit\n* Patients with another condition in the study area.\n* Patients who have received laser treatment for the same condition within the previous 12 months.\n* Patients with another form of rosacea (e.g., papules and pustules, ocular rosacea, etc.).\n* Patients using another anti-redness product on the face during the study.\n* Patients who have taken photosensitizing treatments during the month prior to study enrollment.\n* Patients taking or having taken oral isotretinoin within 6 months prior to study enrollment.\n* Patients enrolled in another study.\n* Adult patients under a legal guardianship arrangement (guardianship, conservatorship, judicial protection).\n* Patients not covered by social security.","ALL","18 Years",{"count":63,"type":64},50,"ESTIMATED","INTERVENTIONAL",[67],"NA","The aim of this clinical study is to evaluate the effectiveness and safety of a dermocosmetic product in reducing facial redness and visible blood vessels associated with erythematotelangiectatic rosacea.\n\nInvestigators will compare the dermocosmetic product to a placebo applied to opposite sides of the face, when used alone and in combination with laser treatment.\n\nParticipants will apply the products twice daily for 2 month followed by continued use in combination with laser treatment, and will attend regular clinical visits for assessments and questionnaires.",[70,71],"Rosacea, Erythematotelangiectatic","Rosacea Subtype 1 (Erythematotelangiectatic)",[73,74,75,76],"Erythematotelangiectatic Rosacea","Telangiectasia","Dermocosmetic","Laser Therapy","NOT_YET_RECRUITING","2026-04-03",{"date":80,"type":81},"2026-04-13","ACTUAL",{"date":83,"type":64},"2026-09-01",{"date":85,"type":64},"2027-06-30",{"name":5,"class":6}]